Archives
Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding
2026-04-23
Angiotensin Peptides Potentiate SARS-CoV-2 Spike–Receptor Interactions: Implications for Cardiovascular and Viral Pathogenesis
Study Background and Research Question
The renin-angiotensin system (RAS) orchestrates critical physiological processes such as blood pressure regulation, fluid homeostasis, and tissue remodeling. Angiotensin peptides, including Angiotensin II (1–8) and its truncated derivatives, are well-known for their vasoactive properties and their central role in cardiovascular physiology. In parallel, the COVID-19 pandemic has drawn attention to RAS components as SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) for cell entry, while additional receptors such as neuropilin-1 (NRP1) and AXL have been implicated in viral tropism.A key unresolved question is whether endogenous angiotensin peptides modulate the interaction between the SARS-CoV-2 spike protein and its host receptors, potentially impacting viral infectivity and disease severity (Oliveira et al., 2025). Understanding these interactions is vital for both hypertension research and emerging viral pathogenesis models.
Key Innovation from the Reference Study
The study by Oliveira et al. provides the first systematic analysis of how various naturally occurring angiotensin peptides—including shorter C- and N-terminal fragments—modulate the binding affinity of the SARS-CoV-2 spike protein to its known receptors. Crucially, the research uncovers that not only full-length Angiotensin II but also truncated peptides such as Angiotensin (1–7), Angiotensin (1–6), Angiotensin IV (3–8), and notably Angiotensin (5–7) (the H2N-Ile-His-Pro-OH peptide) can enhance spike–AXL receptor binding, with some truncated forms exerting even greater potentiating effects than their parent molecules (Oliveira et al., 2025).Methods and Experimental Design Insights
The authors employed quantitative antibody-based binding assays to dissect the interaction landscape between the SARS-CoV-2 spike protein and three key host receptors: ACE2, NRP1, and AXL. A panel of angiotensin peptides—systematically truncated at either the N- or C-terminus—was tested for their capacity to modulate spike–receptor binding. Additionally, the effects of specific amino acid substitutions and post-translational modifications (e.g., phosphorylation) at critical positions (notably Tyr4) were evaluated to reveal structure–function relationships.The approach allowed the team to map the minimal structural motifs required for spike–AXL binding potentiation, and to distinguish effects unique to the AXL receptor versus ACE2 and NRP1. The peptide concentrations and assay conditions were selected to reflect physiologically relevant ranges for both cardiovascular and virology research contexts.
Core Findings and Why They Matter
- Angiotensin II (1–8) increases spike–AXL binding. Exposure to Angiotensin II doubled the binding between the spike protein and AXL, but had no significant effect on spike–ACE2 or spike–NRP1 interaction (Oliveira et al., 2025).
- Truncated angiotensin peptides show distinct, sometimes stronger effects. Shorter peptides such as Angiotensin (1–7), Angiotensin (1–6), and Angiotensin IV (3–8) also enhanced spike–AXL binding to a similar or greater degree than Angiotensin II itself. Notably, N-terminally truncated forms including Angiotensin IV (3–8) and Angiotensin (5–7) (H2N-Ile-His-Pro-OH) produced the most pronounced increase, with Angiotensin IV elevating spike–AXL association by up to 2.7-fold (Oliveira et al., 2025).
- Structure–activity relationship revealed by residue modifications. Substituting valine for tyrosine at position 4 or phosphorylating the tyrosine residue further augmented spike–AXL binding, suggesting a pivotal role for this amino acid in peptide-receptor modulation.
- Receptor specificity is context dependent. While most effects were pronounced for the AXL receptor, Angiotensin IV also enhanced spike protein binding to ACE2 and NRP1, hinting at broader implications for viral entry mechanisms.
Comparison with Existing Internal Articles
Recent internal resources have emphasized the dual role of Angiotensin 1/2 (5-7) as both a vasoconstrictor and a modulator of viral spike protein interactions. For instance, the analysis in "Angiotensin 1/2 (5-7): Mechanistic Leverage and Strategic..." contextualizes this peptide within the broader landscape of renin-angiotensin system research, highlighting its value in both cardiovascular and viral pathogenesis models. Similarly, "Angiotensin 1/2 (5-7): Applied Workflows for Hypertension..." stresses the experimental flexibility afforded by the peptide's high solubility and validated vasoconstrictor activity, noting its application in advanced hypertension and infection studies.The present reference study deepens this perspective by providing direct evidence that truncated angiotensin peptides, including H2N-Ile-His-Pro-OH, can enhance SARS-CoV-2 spike–receptor binding. This mechanistic insight bridges previous workflow recommendations and offers new targets for probing the intersection between blood pressure regulation peptides and viral pathogenesis (Oliveira et al., 2025).
Limitations and Transferability
While the findings robustly demonstrate peptide-mediated enhancement of spike–AXL binding in vitro, several caveats apply:- Physiological concentrations. The concentrations used in binding assays may not directly mirror in vivo peptide levels under physiological or disease conditions (source: workflow_recommendation).
- Complexity of in vivo systems. The interplay between circulating angiotensin peptides and receptor expression dynamics in human tissues, especially during infection or hypertension, requires further investigation (source: workflow_recommendation).
- Specificity for AXL versus other receptors. While the study highlights AXL as a key target, the functional consequences of enhanced spike–AXL binding (e.g., increased infectivity, altered tissue tropism) were not directly assessed (Oliveira et al., 2025).
Protocol Parameters
- binding assay | 1–10 μM peptide | in vitro spike–receptor binding | Reflects physiologically relevant peptide concentrations for mechanistic studies | paper
- binding assay | N/A (modifications: Tyr4→Val, Tyr4 phosphorylation) | structure–activity relationship mapping | Demonstrates the impact of specific amino acid changes on spike–receptor potentiation | paper
- cellular infectivity assay | workflow_recommendation | Application in live cell models | Suggested for downstream validation of spike–receptor potentiation effects | workflow_recommendation
- blood pressure modulation assay | workflow_recommendation | Use in cardiovascular models | Enables study of H2N-Ile-His-Pro-OH as a blood pressure regulation peptide | workflow_recommendation